<DOC>
	<DOCNO>NCT00452413</DOCNO>
	<brief_summary>Phase I : A study see dose Enzastaurin Erlotinib best tolerate participant solid tumor cancer . Phase II : A study see long participant non-small cell lung cancer ( NSCLC ) treat Enzastaurin Erlotinib live .</brief_summary>
	<brief_title>A Study Enzastaurin Erlotinib Participants With Solid Tumors Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Phase 1 : Any incurable solid malignancy , 3 prior systemic treatment regimen . Phase 2 : Histologic diagnosis advance NSCLC , Stage IIIB malignant pleural effusion Stage IV per American Joint Committee Cancer Staging Criteria NSCLC . Participants must fail 1 2 prior systemic treatment regimen ( ) . 2 . Performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) Scale 3 . Prior chemotherapy must complete least 2 week prior study enrollment , participant must recover acute toxic effect ( except alopecia ) prior enrollment . 4 . Prior radiotherapy allow &lt; 25 % bone marrow . Prior radiotherapy must complete least 2 week study enrollment , participant must recover acute toxic effect ( except alopecia ) prior enrollment . 5 . Nonmeasurable measurable disease define Response Evaluation Criteria Solid Tumors [ RECIST , version ( v ) 1.0 ] . Participants 1 . Are unable swallow tablet . 2 . Unable discontinue use carbamazepine , phenobarbital , phenytoin . 3 . Have previously treat epidermal growth factor receptor ( EGFR ) inhibitor , include erlotinib . 4 . Are receive concurrent administration antitumor therapy . 5 . Have receive treatment within last 30 day drug ( include study drug ) receive regulatory approval indication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>